Should MRD Status be used for drug approval? - HealthTree for Multiple Myeloma
[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account

Should MRD Status be used as a good endpoint for drug approval?

Should MRD Status be used as a good endpoint for drug approval? image

Should MRD Status be used as a good endpoint for drug approval?

Webinar
event Jun 23, 2023 / 02:00PM - 03:00PM EDT
link icon facebook logo X logo linkedin logo reddit logo email icon

Event Description

Minimal Residual Disease results come from an extremely sensitive test that detects how many myeloma cells are left in your body after reaching at least a very good partial response from myeloma medications. Some researchers are now wanting to use MRD results as endpoints in clinical trials in order to accelerate drug approval. What are the pros and cons to this proposal? Dr. Syed Abbas Ali shares with us his thoughts on the subject. Come with your questions!

Schedule & Agenda

The panelist Audrey Burton-Bethke
2:00 PM
Introductions
Audrey Burton-Bethke

Audret introduces the agenda of the event and our featured speaker Dr. Syed Abbas Ali.

The panelist Syed Abbas Ali, MBBS
2:05 PM
Presentation
Syed Abbas Ali, MBBS

Dr. Syed Abbas Ali shares with us his thoughts on the subject.

Event panelist Audience
2:35 PM
Questions and Answers
Audience

Type your questions in the chat and we will answer them! 

Speakers & Moderators

The panelist Audrey Burton-Bethke
Audrey Burton-Bethke

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.

Read Bio
The panelist Syed Abbas Ali, MBBS
Syed Abbas Ali, MBBS

Dr. Syed Abbas Ali is a medical oncology specialist in Baltimore, caring for patients with cancer. Dr. Ali earned his M.B.B.S. at The Aga Khan University. He completed his residency at the University of Arkansas for Medical Sciences and performed a fellowship in medical oncology at the National Institutes of Health.

Read Bio
HealthTree Connect Icon

Join the Conversation

This event is part of the Lab Values and Testing group in HealthTree Connect, a social media platform for people with blood cancer. If you want to connect with other patients and caregivers and talk about this topic, join HealthTree Connect.

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

1-800-709-1113

email

Support@healthtree.org

Thanks to our sponsors:
Johnson and Johnson logo
Sanofi logo
Adaptive logo
Pfizer logo
GSK logo
Regeneron logo
All HealthTree resources available anywhere, anytime
Download our App
Download iOS App Download Android App
iphone app mockup
newsletter icon

Get the Latest Chronic Myelomonocytic Leukemia Updates, Delivered to You.

By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.